Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-01

FDA Approved: SPEVIGO — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved SPEVIGO (spesolimab-sbzo) from Boehringer Ingelheim in an original application for generalized pustular psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPEVIGO (SPESOLIMAB-SBZO)

Snippet

ORIG AP for SPEVIGO (SPESOLIMAB-SBZO)